Latest Eddingpharm News
Dec 3, 2019
02:02 EST 3 Dec 2019 | ChinaBio Today EOC Pharma, the oncology development arm of China in- licensing company Eddingpharm, raised $71 million in a Series C round led by Tigermed, TF Capital and Yingke PE. Headquartered in Taizhou, EOC manufactures and commercializes oncology products for China use that require mid to late stage clinical development for registration. It currently has a pipeline of six novel products from global biopharmas, including its most recent in-licensing, a Shionogi HER2/EGFR inhibitor intended to treat brain metastasis in advanced metastatic breast cancer patients. Two years ago, EOC completed a $32 million B financing.